This article was originally published in The Rose Sheet
Executive SummaryFragrance marketer will offer 4,336,050 shares of its common stock in a public offering, firm says Oct. 10. Selling stockholders are LV Capital USA, Inc. (3,436,050 shares), CEO Jean Madar (450,000 shares) and President Philippe Benacin (450,000 shares), according to Inter Parfums. Madar and Benacin additionally will "grant to the underwriters a 30-day option to purchase up to an additional 650,408 shares of Inter Parfums common stock to cover over-allotments, if any," company notes, adding firm "will not receive any proceeds of the sale of its common stock by the selling stockholders." Offering will be managed by Oppenheimer & Co. and SG Cowen & Co., LLC, with Citigroup Corporate and Investment Banking acting as book runner...
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.